Your browser doesn't support javascript.
loading
In vitro assessment of the Kirpa Kit™ modified manual single lumen alternating micro-batch (mSLAMB) dialysis device.
Ceschia, Giovanni; Slagle, Cara L; Morgan, Jolyn; Snyder, Amanda; Rose, James E; Plute, Ed; Chawla, Apaara K; Coriolan, Rebecca; Soranno, Danielle E; Goldstein, Stuart L; Hasson, Denise C.
Afiliación
  • Ceschia G; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. gio.ceschia@gmail.com.
  • Slagle CL; Department for Women's and Children's Health, University Hospital of Padua, Padua, Italy. gio.ceschia@gmail.com.
  • Morgan J; Riley Hospital for Children, Indianapolis, IN, USA.
  • Snyder A; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Rose JE; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Plute E; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Chawla AK; Stavro Medical Inc., San Diego, CA, USA.
  • Coriolan R; George Washington University, Washington, DC, USA.
  • Soranno DE; New York University Langone Health, New York, NY, USA.
  • Goldstein SL; Riley Hospital for Children, Indianapolis, IN, USA.
  • Hasson DC; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Pediatr Nephrol ; 2024 Aug 02.
Article en En | MEDLINE | ID: mdl-39093453
ABSTRACT

BACKGROUND:

Access to pediatric dialysis is challenged in low-resource settings due to high costs, scarcity of equipment, and the lack of qualified personnel availability. We demonstrated the manual single lumen alternating micro-batch (mSLAMB) device can remove small solutes in vitro without the need for electricity, batteries, or pumps. We developed a new version (Kirpa Kit™) to address some of the technical limitations of mSLAMB. Here, we compare the in vitro clearance performance and ease of use of the Kirpa Kit™ with that of prior mSLAMB configurations.

METHODS:

A mixture of expired packed red blood cells, 0.9% NaCl, urea, and heparin was used to test the efficiency of two mSLAMB configurations and the Kirpa Kit™ in removing potassium and urea. Clearance was evaluated by measuring percent reduction after 25-min sessions with each device. A survey was used to evaluate the ease of use of each configuration.

RESULTS:

The Kirpa Kit™ achieved a median urea reduction of 82.4% and potassium reduction of 82.1%, which were higher than those achieved with the best-performing mSLAMB configuration (urea 71.9%, potassium 75.4%). The Kirpa Kit™ was easier to use with a shorter perceived time of use than the mSLAMB.

CONCLUSIONS:

The Kirpa Kit™, evolution of mSLAMB, is easy to use and may have improved efficacy, making it an optimal candidate for in vivo testing.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania